This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jansen, E. P.M. Articles by van de Velde, C. J.H. Search for Related Content PubMed PubMed Citation Articles by Jansen, E. P.M. Articles by van de Velde, C. J.H. Social Bookmarking                            What's this?

Optimal Locoregional Treatment in Gastric Cancer

Edwin P.M. Jansen, Henk Boot, Marcel Verheij, Cornelis J.H. van de Velde

From the Department of Radiotherapy and Gastroenterology of the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam; Department of Surgery, Leiden University Medical Center Leiden, the Netherlands

Address reprint requests to Cornelis J.H. van de Velde, MD, PhD, Department of Surgery, K6-R, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, the Netherlands; e-mail: c.j.h.van_de_velde{at}lumc.nl.

Worldwide, gastric cancer is one of the leading causes of cancer-related death. The mainstay of curative treatment is radical surgery. But even with optimal surgical resection, the prognosis remains modest in the Western world. Numerous attempts have been undertaken to improve clinical outcome. More extensive lymph node dissection, adjuvant radiotherapy and adjuvant chemotherapy did not result in a survival benefit in randomized trials. Only postoperative chemoradiotherapy has proven to be valuable in prospective randomized trials. Questions are to be answered about optimization of surgery, radiotherapy and chemotherapy, and fine tuning of the three modalities. One of the key issues that should be addressed is whether pre- or postoperative chemoradiotherapy will benefit survival or locoregional control in the case of optimal surgery with an "over-D1" lymphadenectomy and without splenectomy. In this article the most relevant literature on locoregional treatment in operable gastric cancer will be reviewed and future strategies will be discussed.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. Bhargava VEGF kinase inhibitors: how do they cause hypertension? Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2009; 297(1): R1 - R5. [Abstract] [Full Text] [PDF]

				S. Biswas, J. Kelly, and T. Eisen Cytoreductive Nephrectomy in Metastatic Clear-Cell Renal Cell Carcinoma: Perspectives in the Tyrosine Kinase Inhibitor Era Oncologist, January 1, 2009; 14(1): 52 - 59. [Abstract] [Full Text] [PDF]

				N. Ahuja Four Hundred Consecutive Total Gastrectomies for Gastric Cancer--Invited Critique Arch Surg, August 1, 2008; 143(8): 775 - 775. [Full Text] [PDF]

				N. I. Khushalani Cancer of the Esophagus and Stomach Mayo Clin. Proc., June 1, 2008; 83(6): 712 - 722. [Abstract] [Full Text] [PDF]

				Z. Zhu, F. Li, Y. Mao, W. Cheng, X. Cheng, and Y. Dang Improving Evaluation of Primary Gastric Malignancies by Distending the Stomach with Milk Immediately Before 18F-FDG PET Scanning J. Nucl. Med. Technol., March 1, 2008; 36(1): 25 - 29. [Abstract] [Full Text] [PDF]

				S. Cascinu, R. Labianca, C. Barone, A. Santoro, C. Carnaghi, A. Cassano, G. D. Beretta, V. Catalano, O. Bertetto, S. Barni, et al. Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients With 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial J Natl Cancer Inst, April 18, 2007; 99(8): 601 - 607. [Abstract] [Full Text] [PDF]

				A. Marchet, S. Mocellin, C. Belluco, A. Ambrosi, F. DeMarchi, E. Mammano, M. Digito, A. Leon, A. D'Arrigo, M. Lise, et al. Gene Expression Profile of Primary Gastric Cancer: Towards the Prediction of Lymph Node Status Ann. Surg. Oncol., March 1, 2007; 14(3): 1058 - 1064. [Abstract] [Full Text] [PDF]

				J. A. Garcia and B. I. Rini Recent Progress in the Management of Advanced Renal Cell Carcinoma CA Cancer J Clin, March 1, 2007; 57(2): 112 - 125. [Abstract] [Full Text] [PDF]

				A. Polverino, A. Coxon, C. Starnes, Z. Diaz, T. DeMelfi, L. Wang, J. Bready, J. Estrada, R. Cattley, S. Kaufman, et al. AMG 706, an Oral, Multikinase Inhibitor that Selectively Targets Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors, Potently Inhibits Angiogenesis and Induces Regression in Tumor Xenografts. Cancer Res., September 1, 2006; 66(17): 8715 - 8721. [Abstract] [Full Text] [PDF]